Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerance: Doxorubicin vs Cyclophosphamide + Prednisolone in elderly advanced soft tissue sarcoma
NCT04780464Phase 3Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Apr 2022
- Primary completion
- Sep 2023
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 2
01
Overview
A Phase 3 trial of pegylated liposomal doxorubicin, cyclophosphamide in soft tissue sarcoma (STS), sponsored by European Organisation for Research and Treatment of Cancer. Started Apr 2022; status: terminated.
02
Drugs
pegylated liposomal doxorubicincyclophosphamide
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT04780464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04780464.